Study on 18F-Fluciclovine PET/CT for Improved Detection in Multiple Myeloma
A clinical trial is underway to evaluate the efficacy of 18F-fluciclovine PET/CT compared to 18F-FDG in detecting multiple myeloma.
Phase III
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of 18F-fluciclovine PET/CT could significantly alter diagnostic practices in multiple myeloma, potentially replacing the current standard imaging agent, 18F-FDG. This shift may influence product development strategies for companies involved in imaging agents and diagnostics.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results on detection rates and overall survival outcomes as the trial progresses.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.